Boston Scientific (BSX) 10-K2007 FY Annual report

Filed: 28 Feb 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Good

New words: abatement, ACUITY, Addiction, addressing, Adjunct, Africa, aggravated, aimed, Ark, Arrow, attrition, Avid, Avista, bar, baseline, Bausch, BB, beneficiary, Blazer, BP, cadence, Calvert, Capnia, Celgene, Celsion, Centricity, CFG, chamber, chromium, CONFIENT, Congressional, content, count, CRT, crucial, deadline, diabetic, die, distraction, divestiture, earliest, East, EBI, editorial, eighteen, Elliott, EMEA, EMR, ENDOTAK, entrant, exploration, explore, expressly, fewer, fifty, fined, flagship, Fraser, gas, GE, Geography, Getinge, goal, greenhouse, Grove, handler, HUD, improperly, inception, INGENIO, instructed, IP, IPO, joint, Kassel, lab, land, Latin, lawyer, LEED, Leno, Lessee, LIVIAN, Lomb, lost, manifested, Maple, Marlborough, McFaul, metric, monetization, monetize, monetized, monetizing, morale, Nashville, Naval, NeuroForm, oppose, OREF, Orthopaedic, orthopedic, outplacement, overfunded, oversaw, oversee, PCI, Philanthropy, platinum, pled, pose, postretirement, principle, prove, Provost, Quincy, randomized, ratified, Raymond, reaction, rebuild, recalculate, recalculated, reconsider, rehear, Remon, renegotiate, renovation, residual, rest, resume, rollforward, run, Sam, SAS, SciCo, SCS, seventeen, Simon, simplified, smallest, South, Spark, SPIE, stewardship, Stonebridge, store, Street, Stryker, sublicensed, Substance, surveillance, suspension, symptomatic, Tec, TELIGEN, TomoTherapy, Topic, true, trunk, underfunded, unintended, unrecognized, unreduced, unsupported, USCAP, valuable, VIE, view, vision, voluntarily, winning, Wyeth, Zimmer, Zwirn

Removed: accomplished, Aikman, Alan, anatomy, announcement, Antoinette, Australia, Bankruptcy, bion, Biotech, calculating, called, Chapter, circumstance, commenting, dating, deemed, deepen, economically, effected, Enteric, enteryx, EPI, excellent, expedited, favorably, fellowship, flexibility, Goodman, Gymea, holding, HTA, impacting, inflow, Intercontinental, Kent, lawrence, leveraged, linked, Loeffler, Markle, Mary, matured, meaningful, microcatheter, microstimulator, migraine, mitigate, motivated, multinational, neurostimulation, operation, optimization, optimizing, origin, paper, planning, polymer, precise, Presidential, processor, programmable, prohibitive, putatively, PVS, QMed, refiled, relationship, released, repeat, replenish, Schuster, segmented, sequence, serving, site, sizeable, skin, strong, structured, suspended, swap, Sydney, transform, Triad, unavailable, virtually

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BSX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.

SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

(1)

the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.



By:	/s/ James R. Tobin
	James R. Tobin
	President and Chief Executive Officer

February 27, 2008